The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2020 | Waldenstrom’s macroglobulinemia in the era of immunotherapy
Waldenström macroglobulinemia is a rare hematological cancer characterized by an excess of abnormal lymphoplasmacytic cells in the bone marrow and is classified as a lymphoplasmacytic lymphoma. Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, discusses the treatment of Waldenstrom’s macroglobulinemia in the era of immunotherapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
